Categories
Product

OMNY Health Achieves HITRUST e1 Certification: A Milestone in Healthcare Data Security

We at OMNY Health are thrilled to announce that the OMNY Health Platform has successfully achieved HITRUST e1 Certification, a landmark achievement in our ongoing commitment to foundational cybersecurity controls and information risk management in healthcare. 

HITRUST e1 Certification focuses on foundational cybersecurity and the most critical set of controls for essential cybersecurity hygiene. This certification demonstrates that OMNY’s Ecosystem Platform has a comprehensive set of rigorous controls and best practices in place for essential for cybersecurity hygiene and protecting sensitive information. 

“The HITRUST e1 Validated Assessment is a good tool for cyber-aware organizations like OMNY HEALTH that want to build assurances and progressively demonstrate due diligence around information security and privacy,” said Robert Booker, Chief Strategy Officer at HITRUST. “We applaud OMNY HEALTH for their commitment to cybersecurity and successful completion of their HITRUST e1 Certification.” 

Achieving HITRUST Certification is no small feat. It represents countless hours of hard work, meticulous attention to detail, and an unwavering commitment to excellence from our entire team. This certification validates our robust approach to data security and privacy, covering 19 domains of information security. 

“The HITRUST e1Certification is more than just a badge of honor – it’s a rigorous, comprehensive validation of our security practices,” said Dr. Maik Lindner, OMNY’s Chief Information Security Officer.  “This achievement demonstrates that we’ve implemented a robust set of controls that meet the unique challenges of protecting sensitive healthcare data. It’s a reflection of our proactive approach to security and our commitment to staying ahead of evolving cyber threats in the healthcare industry.” 

For our health system partners, the HITRUST Certification of our platform offers several key benefits:

  • Enhanced Trust: You can be confident that your data is protected by security measures that meet or exceed industry standards.
  • Simplified Compliance: Our certification helps streamline your compliance efforts, particularly with regulations like HIPAA. 
  • Reduced Risk: With our certified security framework, the risk of data breaches and associated costs is significantly reduced.
  • Improved Interoperability: Our certification enhances our ability to securely share and process data across the healthcare ecosystem.

“Achieving HITRUST certification is a testament to our unwavering commitment to data security and privacy in healthcare. This milestone reflects the dedication of our entire team and reinforces our position as a trusted partner in the healthcare data ecosystem. We’re proud to offer our health system partners the highest level of assurance in data protection, allowing them to focus on what matters most – improving patient outcomes,” said Dr. Mitesh Rao, CEO. 

At OMNY, we view this certification not as a final destination, but as a milestone in our ongoing journey of excellence. We are committed to:

  • Continuously improving our security measures 
  • Staying ahead of emerging threats in the digital healthcare landscape
  • Providing our partners with the highest level of data protection 

As we celebrate this achievement, we want to thank our dedicated team and our valued partners for their trust and support. We look forward to continuing our mission of advancing healthcare through secure, innovative data solutions.

Categories
Product

Does Implant Design Matter? Studying Total Knee Arthroplasty in Clinical RWD

Knee replacement surgery has advanced significantly over the years, with innovations in implant design aimed at improving patient mobility and long-term outcomes. However, when it comes to single-radius (SR) vs. multi-radius (MR) femoral implants, how much of an impact does design really have on patient recovery and healthcare utilization? While clinical trials provide controlled comparisons, real-world evidence offers a broader perspective on outcomes across diverse patient populations.

To better assess these differences, OMNY Health analyzed real-world data from its orthopedic-focused medtech dataset, evaluating clinical, functional, and economic outcomes in TKA patients.

Comparing Implant Design in Real-World Settings

This study leveraged data from the OMNY Health Medical Device Database (2017-2021), examining 1,464 patients who underwent unilateral TKA. Patients were categorized into SR (N=1,135) and MR (N=329) cohorts, allowing for direct comparisons of key outcomes.

Patient Demographics:

  • Most patients were born between the 1950s and 1960s (SR: 59%, MR: 57%).
  • Women accounted for the majority of cases (SR: 63%, MR: 70%).
  • The SR cohort had a higher proportion of White patients (85%) compared to the MR cohort (75%).
  • More MR patients underwent outpatient procedures (53%) compared to SR patients (43%).

Key Findings: Minimal Differences Between Implant Designs

Despite prior speculation that implant design could significantly impact outcomes, this real-world analysis found that SR and MR implants performed similarly across key measures.

Clinical Outcomes:

  • Mortality rates were low in both cohorts (SR: 1.1%, MR: 0.3%).
  • Postoperative knee pain was reported at comparable rates (SR: 0.6%, MR: 1.2%).
  • Implant removal was rare, with no significant difference observed (SR: 0.4%, MR: 0.0%).

Functional Outcomes:

  • Non-routine discharge disposition (NRDD) rates were identical (SR: 16.4%, MR: 16.4%), suggesting that implant design did not influence post-surgical mobility.

Economic & Utilization Outcomes:

  • Length of stay (LOS) was similar across groups (SR: 0.98 days, MR: 0.96 days).
  • Gross charges were slightly higher for SR patients (Median: $43,879 vs. $39,255 for MR), though differences may be driven by factors beyond implant design.

What This Means for Clinical Decision-Making

The findings suggest that implant design alone does not significantly impact clinical or functional outcomes in TKA patients. Instead, factors such as surgical technique, rehabilitation protocols, and patient-specific factors play a more substantial role in determining recovery and long-term success.

For healthcare providers and medtech companies, these results highlight the value of real-world data in refining orthopedic product development and post-market surveillance. While MR designs have been thought to provide more natural knee movement, this study suggests that real-world functional outcomes do not differ significantly between SR and MR implants.

Additionally, the slight difference in cost between implant types warrants further investigation to determine cost-effectiveness in value-based care models.

The Role of Real-World Data in Orthopedic Research

By integrating structured EHR data with curated clinical measures, OMNY Health provides real-world insights into medical device performance. This data-driven approach enables:

  • Comparisons of implant designs and surgical techniques to refine best practices.
  • Better understanding of patient recovery patterns and healthcare utilization.
  • Support for evidence-based decision-making to optimize orthopedic device selection and patient outcomes.

With orthopedics as a key therapeutic area for medtech innovation, leveraging real-world evidence is essential for ensuring high-quality, cost-effective decision-making in TKA and beyond.

Categories
Product

Breaking Barriers in Sickle Cell Care: Real-World Insights on Treatment & Healthcare Utilization

Breaking Barriers in Sickle Cell Care: Real-World Insights on Treatment & Healthcare Utilization

Sickle cell disease (SCD) presents unique challenges for patients and healthcare providers alike. To better understand these challenges, OMNY Health analyzed real-world data (2017-2024), leveraging its unique ability to integrate structured EHR data with curated clinical measures to provide a comprehensive view of SCD patients. This study examined the demographics, healthcare utilization, and treatment patterns of 10,958 individuals diagnosed with SCD.

Disproportionate Burden and Frequency of Healthcare Use in Sickle Cell Disease

SCD remains a condition that disproportionately affects minority populations. Among the studied population:

  • 82% identified as Black, with additional representation from Hispanic and Asian/Pacific Islander groups, emphasizing racial disparities in disease burden and healthcare access.
  • The average age of patients was 37 years, showing that SCD continues to impact individuals well into adulthood.

Figure 1. Demographic Characteristics of Patient Population

bar chart showing demographic characteristics among patients with sickle cell

At the same time, these patients experience high levels of healthcare utilization:
  • 66% had an emergency room visit.
  • 65% required outpatient care.
  • 4.3 inpatient admissions per patient on average, though some required over 185 hospital stays.

Comorbidities and Limited Treatment Utilization for Sickle Cell Disease

OMNY Health’s curated datasets capture a wide range of comorbidities, helping to broader clinical patterns that impact SCD progression. Among the most common conditions observed:

  • Anemia, chronic pain, and hypertension, which are linked to SCD progression.
  • Gastroesophageal reflux disease (GERD), urinary tract infections, and vitamin D deficiency, highlighting broader health vulnerabilities.

These figures suggest that many individuals with SCD struggle with disease management, pain crises, and complications that lead to recurring hospital visits. The high frequency of inpatient admissions, even among younger adults, indicates that preventive strategies may not be reaching those who need them most. Many hospital stays are driven by acute complications, highlighting the importance of early intervention and better access to disease-modifying treatments that could reduce the need for emergency care.

 Table 1: HCRU Among Individuals with SCD

Figure 2: Top clinical comorbidities among individuals with SCD

Despite available treatments, adoption remains low:

  • 11.3% of eligible patients received hydroxyurea, the most used therapy.
  • Less than 1.1% of patients received newer disease-modifying treatments, such as Crizanlizumab, Voxelotor, L-glutamine, or Stem Cell transplants.

This raises concerns about barriers to access, including cost, provider awareness, and prescribing patterns. Through OMNY Health’s ability to track real-world prescribing trends and treatment adherence, stakeholders can better understand where interventions are needed to improve access.

Moving Forward with Data-Driven Solutions

By leveraging OMNY Health’s robust real-world data, we can provide critical insights into treatment patterns, healthcare utilization, and patient needs. OMNY Health’s curated data and clinical measures enable a more complete understanding of SCD care gaps, supporting efforts to inform policy changes, optimize treatment strategies, and enhance healthcare provider decision-making

For more information about OMNY Health’s product offerings, let’s connect!

Categories
Product

Unlocking Real-World Insights into IBD Treatment: The Power of Clinical EHR and Physician Notes Integration

At OMNY Health, we believe that unlocking the full potential of healthcare data means going beyond structured fields in Electronic Health Records (EHRs). By combining EHR data with unstructured clinical notes, we can uncover insights that truly reflect the complexities of patient care—insights that are often hidden in claims or EHR data alone.

Our recent study on Inflammatory Bowel Disease (IBD) treatment patterns highlights the unique value of integrating EHR data with clinical notes. Using Large Language Models (LLMs), we analyzed over 10.6 million clinical notes from our health systems to explore why IBD patients switch or discontinue biologic treatments. This approach gave us a comprehensive, real-world view of treatment decisions. We identified 7 distinct reasons for treatment alteration across 7 biologics.

Key Findings: Uncovering the Real Reasons for Treatment Changes

While traditional EHRs track structured data like medication prescriptions and diagnoses, they often miss the “why” behind treatment decisions. Our study revealed seven key reasons why biologic treatments are altered, based on unstructured notes that provide deeper context:

  • Adverse Drug Events (16-28%)
  • Finance-Related Reasons (4-24%)
  • Patient-Related Factors (2-9%)
  • Lack of Efficacy (1-14%)
  • Symptom Resolution (1-4%)
  • Drug-Disease Interactions (1-3%)
  • Obstetric Concerns (0-2%)

Figure 1. Reasons for Biologic Switching in IBD

Biologic Adverse Drug Event (%) Drug-Disease Interaction (%) Symptom Resolution (%) Finance Related (%) Patient Related (%) Not Effective (%) Obstetric (%)
Infliximab 28.26 1.92 2.87 24.42 8.62 14.37 0.48
Adalimumab 26.82 2.87 1.44 12.93 8.14 2.87 1.92
Golimumab 0.96 0 0.48 1.44 0.48 0 0
Certolizumab 1.92 0 0 0.96 0 0 0
Vedolizumab 16.28 0.96 4.31 7.18 6.70 1.44 1.92
Ustekinumab 11.01 0.48 0 3.83 2.39 0 0
Risankizumab 0.96 0 0 0 0.48 0 0

Transforming IBD Care: From Data to Insight

By analyzing clinical notes, OMNY Health’s AI models identified reasons for treatment alterations with 94.5% accuracy. This level of insight isn’t typically captured in structured EHR fields, and it has significant implications for improving patient care.

Understanding the real-world reasons behind treatment changes is essential for refining treatment strategies, improving adherence, and ultimately achieving better patient outcomes. For IBD patients, this means more personalized care tailored to their unique circumstances—whether that’s a financial hurdle, an adverse drug reaction, or a need for a more effective therapy.

The Future of Healthcare Data: A New Era of Personalized Care

At OMNY Health, we’re excited about the future of healthcare data. By integrating EHRs with unstructured clinical notes and leveraging the power of AI, we can identify patterns that were previously overlooked. This approach not only improves our understanding of IBD treatment but also has the potential to transform how we approach care across a wide range of conditions.

Categories
News Product

OMNY Health launches new GI real-world data solutions in partnership with leading US gastroenterology practices

OMNY Health’s GI partnerships are a pivotal step in its mission to deliver data and insights to accelerate life-changing innovation. With a focus on catalyzing research and improving outcomes, OMNY aims to make a tangible difference for the millions of individuals in the US impacted by gastroenterology diseases

ATLANTA, GA, April 22, 2024 – OMNY Health is pleased to announce its partnership with the nation’s leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research. Over 5,000 GI providers serving more than 10 million patients are now part of OMNY’s research network, representing care delivery by over 380,000 providers and 75 million patients across the US. The focus on GI practice data is a notable expansion to OMNY’s real-world data ecosystem, which works with providers to support compliant research partnerships at scale. OMNY works with the health systems to enable insights on patient population characteristics, care delivery patterns, and treatment outcomes based on data extracted from de-identified inpatient and ambulatory care electronic health records (EHRs). OMNY’s solutions deliver valuable information on disease severity, rationale behind treatment decisions, treatment efficacy, and impact of social determinants on treatment selection and disease progression. By integrating disparate EHRs into unified, de-identified research data products, OMNY offers researchers and providers the breadth and depth of information needed to address their biomedical and population health research questions.

“United Digestive remains committed to offering our patients the most suitable and cost- effective healthcare solutions. Our dedication to delivering best-in-class GI care is intricately linked with our data-driven approach,” says United Digestive’s Chief Medical Officer, Dr. John Suh. “We are thrilled to announce our partnership with OMNY Health, which allows us to drive further insights from our data to advance patient care.”

“As Florida’s leading gastroenterology provider, Borland Groover’s mission is to provide exceptional care and improve the lives of our patients. Achieving this objective requires a deep understanding of our patients, patterns of care, outcomes, and opportunities for further improvement through data analysis,” said Borland Groover’s CEO, Dr. Kyle Etzkorn. “Our collaboration with OMNY not only aligns with our mission, but it also presents avenues to identify and pursue future opportunities for elevating GI patient care.”

“Enhancing patient care isn’t just a goal; it’s our responsibility, guided by the personal experiences of every patient we serve. Each piece of patient data is not just a statistic; it is a pathway to better outcomes, a testament to our commitment, and a source of inspiration for ongoing progress” said Christa Newton, MBA, CEO, OneGI. “We are excited to partner with OMNY as a tangible step in realizing these guiding principles for the benefit of our patients.”

“It is important to One GI that our patients are represented when it comes to emerging research, care improvement initiatives, and best in class care. Our partnership with OMNY helps ensure our providers have the data and support they need to deliver easy to access exceptional GI care.” – Dr. Michael Dragutsky, Founder, Chairman, OneGI. Key populations available in the GI specialty offerings are aligned with the significant research and development efforts underway in gastroenterology, including ulcerative colitis, Crohn’s disease, celiac disease, short bowel syndrome, reflux disorders, and many others. Like other OMNY Health specialty-focused solutions, the GI offering includes information covering pharmacy orders, lab and diagnostic test results, comorbidities, symptom checklists, and provider clinical assessment scores. “We are thrilled to welcome our new gastroenterology providers to our network. Over the past two years, we have made great strides connecting researchers and providers participating in our dermatology and ophthalmology research networks. We look forward to building on that impact in the field of gastroenterology,” said Mitesh Rao, MD, CEO, OMNY Health.

About OMNY Health

OMNY Health connects the healthcare ecosystem through data and insights to transform healthcare delivery, improve clinical outcomes, and address patients’ unmet needs.   The OMNY platform serves as a centralized resource for healthcare stakeholders to participate in data sharing and research services at scale, fueling innovation where patients need it the most. For more information, go to https://marketing-dev.omnyhealth.com/

MEDIA INQUIRIES: media@omnyhealth.com 

Categories
News Product

Five Natural Language Processing Subtasks that Large Language Models Can Perform to Improve Healthcare

In late 2022, the technology world was turned upside down as OpenAI released ChatGPT, its new artificial intelligence (AI) model.  Unlike most previous natural language processing (NLP) models, this model contained billions of parameters, was trained on a corpus of unstructured data with unprecedented size, and underwent a novel alignment process to better orient the model towards human needs.  The result was a model that provided superior performance for various NLP-related tasks and professional certification exams (including medical ones) and could produce realistic-sounding text that even the most hardened AI cynics could not deny.  Technological and legal impacts were felt almost immediately. Many technology companies began to invest in the new field of generative artificial intelligence (genAI) with an eye toward the potential for financial benefits. 

However, lost in all the excitement, is the fact that genAI relies largely on the bread-and-butter NLP methods and subtasks that have supported and improved many industries, including healthcare, over the past decade or two, with the additional capability of text generation.  Unlike previous NLP models, newer large language models (LLMs) can perform many different NLP subtasks with one single model. 

So, what are the different subtasks that a state-of-the-art LLM can perform? Without further ado, here are five NLP subtasks that can be programmed into LLM to improve healthcare:

Text Classification

Text classification, or the task of distributing text into categories, is often seen as the most primitive NLP subtask.  A classic non-healthcare example of this subtask is categorizing reviews (e.g., critiquing products or movies) into having positive or negative sentiments. Text can be classified at the sentence or paragraph level, depending on the use case.   

In healthcare, the clinical notes for patients can be classified as to whether they identify patients as having certain attributes or disease characteristics.  Using that information, appropriate personalized interventions and treatments can then be used to improve health.  Over the past year, work at OMNY Health has focused on several text classification projects, including the following:

  1. Classifying generalized pustular psoriasis (GPP) patients or patients with a rare, devastating form of the skin disease psoriasis, by their disease status (flare versus non-flare) in collaboration with a life sciences partner. 
  2. Classifying psoriasis patients as to whether they received joint assessments and/or rheumatology referrals in the presence of psoriatic arthritis symptoms, in collaboration with life sciences partners. 
  3. Identifying patients adversely affected by social determinants of health, including illiteracy and financial and housing insecurity. 

The results of the study are available.

Named Entity Recognition

Also known as token classification, named entity recognition (NER) involves classifying individual words or phrases as reflective of an entity, for example, a person, place, or organization.  It differs from text classification in that every word is classified, unlike text classification in which sentences and paragraphs are classified.

In healthcare, common entities detected include symptoms, medications, and protected health information (PHI). PHI may be related to individuals, such as names, addresses, and contact information, in larger efforts to deidentify clinical notes before their input in an NLP model.  In fact, at OMNY Health, more than 20 PHI entities are identified and removed from clinical text before NLP to protect patient privacy and to comply with the Health Insurance Portability and Accountability Act (HIPAA) of 1996.

Relation Extraction

Relation extraction (RE) represents a relatively more complex subtask in which the relationships between various entities are determined.  For example, if two “person” entities are detected in the text, an RE task may be used to identify whether the two entities are married.  It is usually performed downstream of an NER step.  Previously, RE tasks often required expensive annotation and labeling processes to be performed successfully, although this requirement has faded with the advent of newer LLMs that can label and annotate notes automatically.

In healthcare, RE applications include identifying patient-doctor relationships for clinical note understanding, as well as more general clinical RE to model medical knowledge ontologies such as the Systematic Nomenclature in Medicine – Clinical Terms (SNOMED-CT).  At OMNY Health, work has been performed to identify relations between detected symptom and medication entity-pairs to determine if they comprised an adverse drug event (ADE).

Closed-domain Question Answering

Closed-domain question answering is an NLP subtask in which a text is paired with a question about the text, like a reading comprehension question on a standardized exam.  The question-context pair is then passed to an NLP model, which then extracts the answer to the question from the text.

In healthcare, question-answering pipelines can be performed to extract practically any conceivable information about a patient from clinical notes, when paired with the correct prompt.  The answer can then be processed and refined using additional NLP steps.  As an example, a clinical note about medication discontinuation could be passed as input to an NLP model paired with the question, “Why was the medication discontinued?”  The answer could then be passed to a text classification model which categorizes the reason for treatment discontinuation.  At OMNY Health, we have constructed such a pipeline to determine reasons for treatment discontinuation for various medications.  A second application of question-answering is the extraction of severity scores from clinical notes for various diseases.

Text Generation

Finally, text generation is the process of composing new, original text in response to a provided prompt.

The basic mechanism revolves around predicting the next word based on the input prompt and the sequence of previously generated words.  As alluded to in the introduction, modern LLMs undergo alignment to prevent toxic, irrelevant, and/or unhelpful text from being generated. This has resulted in improved output.  Text generation can be used for open-domain question answering, in which a general prompt is provided with no corresponding answer in the context (e.g. “What is the purpose of life?”).  Text generation is also used on the downstream end of retrieval-augmented generation pipelines, in which a query first causes the NLP pipeline to filter the relevant documents in a database, extract an answer, and then generate text to present the answer to the user.

In healthcare, potential applications of text generation include helping physicians write clinical notes to ease documentation burden, as well as simplifying routine tasks for health analysts at pharmaceutical companies.  A true challenge is to accomplish these use cases while protecting patient privacy and preventing any PHI leakage in responses to prompts.  At OMNY Health, we strive to accomplish these and related use cases responsibly.

Conclusion

In conclusion, there is more to LLMs than generating text.  Combining text generation functionality with the subtasks mentioned in this article potentiates LLMs to complete powerful tasks that can help improve healthcare.

Categories
Product

Accelerate the Pace of Life-Changing Innovation

Hidden deep in healthcare data lies powerful insights and clinical revelations. Knowledge, that when shared with healthcare visionaries, can spark actions that will accelerate the pace of life changing innovations.  Curating this wealth of knowledge requires precise data handling and a sharp focus on balancing two important factors:  Patient Privacy and Care Innovation.  

OMNY Health’s technology solutions deliver immediate value to Life Sciences researchers by delivering standardized patient, encounter, notes, and supply data from a diverse set of providers in a secure cloud platform. With off-the-shelf data, dashboards, reports, and analytics available in a variety of formats and combinations, time to insights and decisions accelerate, so your team can focus on improving access to effective treatments and transforming the lives of patients. OMNY works closely with integrated delivery networks, community hospital systems, and even specialty practices to harmonize their data, enable custom analytics and create a real-word data pipeline. 

These clinical insights are shared with Life Sciences companies for use in expediting Research & Development, driving new therapy launches and accelerating commercialization strategies. And while providers and pharmaceutical innovators benefit significantly from the standardization and flow of useful data, the ultimate winners are the patients.

Here’s an example:

Working with 2 health systems, we uncovered insights that directly informed treatment decisions for Myasthenia Gravis, or MG, patients and powered pre-launch research for a new innovative MG drug . What’s more, we provided real-world context to understand MG therapy burden and barriers to care.

Healthcare data holds the promise of clinical innovation. OMNY can connect you with the quality data you need to inform and transform actions that will make a real difference in patients’ lives. The future of healthcare is accessible today.

 To learn more about this story and how to partner with OMNY Health, please contact us.

Categories
Product

How OMNY Health™ Is Supporting the Fight Against MG

OMNY Health™ worked closely with an innovative pharmaceutical company to support the launch of its Myasthenia Gravis (MG) drug by providing data from two of its health system partners.

Compiling in-depth information from more than 30 of our partnered medical facilities, we delivered a snapshot of the real-world healthcare encounters and treatment experience for over 1,700 patients via a secure, de-identified dataset. The OMNY Health Insights professional services team delivered dashboards characterizing the patient journey from initial interaction points to ultimate diagnosis and treatment, a solution that the pharma company’s claims data supplier could not provide. 

Of note, the insights collected enabled deeper insights into both inpatient and outpatient settings, as well as the broad spectrum of medical specialists delivering the care. Not surprising, variation in care was identified across physician specialty.

Armed with this data, our customer has optimized access to its product for patients in need. The insights our team provided allowed their global rare disease experts to better understand patient journeys without compromising privacy. 

Funds from this engagement have already routed back to the participating health systems for reinvestment, empowering them to hire more staff, improve frontline staff salaries, address budget challenges, and invest in new medical equipment. 

To learn more about this story and how to partner with OMNY Health, please contact us.

Categories
Product

OMNY Health’s Provider Leadership Council

OMNY Health™ is establishing a new Provider Leadership Council (PLC), comprised of executives from leading health systems and specialty networks interested in collaborating on opportunities to leverage real-world data and evidence to address the strategic imperatives facing the U.S. healthcare system.

The intent of the PLC is grounded in our vision for OMNY Health – to support providers in extracting value from their real-world data assets that frequently reside across disparate, fragmented information systems.  

We are inviting health system executives from large integrated networks and specialty medical groups to join us and help drive better evidence-based decisions across the industry. 

We believe this initiative will help health systems who are looking to address issues such as health equity, value-based care reimbursement, adapting to telemedicine/telehealth, as well as enabling patient-centered care initiatives.  Data and analytics will play a critical role in planning, executing, and evaluating the impact of approaches focused on tackling these challenges. 

The benefits of participating in the Provider Leadership Council include:

  • Early access to new features and functionality on the OMNY Health Platform
  • Opportunities to collaborate with OMNY Health on product strategy initiatives
  • Research initiatives to drive additional clinical research opportunities to provider institutions
  • Access to cutting edge technology such as AI and blockchain
  • Networking opportunities with opinion leaders and industry experts

OMNY Health plans to kick off the PLC in March 2021 (updated).  If you are a health system leader who would like to get involved or simply learn more, please contact us today.